Advertisement
GH vs NTRA
Which Stock Would AI Choose? Guardant Health (GH) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Both GH and NTRA are liquid biopsy and molecular diagnostics leaders riding strong, multi-year uptrends, but they differ sharply in scale, diversification, and near-term valuation.
- GH has shown stronger recent price momentum, rising roughly 144% over the trailing year, while NTRA has gained around 75–80% over a comparable stretch.
- NTRA is the larger, more diversified franchise with roughly $2.9 billion in expected 2026 revenue, versus about $1.36 billion for GH.
- Analyst consensus is "Strong Buy" on both names, but GH trades with materially more implied upside to its average price target than NTRA, which sits near its target and its 52-week high.
- Tickeron AI Verdict: Based on momentum, catalyst pipeline, and relative valuation, Tickeron's AI would currently lean toward GH (Guardant Health) as the favored name in this stock comparison.
- For more detail, explore GH Major News and GH Today's Price Move, along with NTRA Major News and NTRA Today's Price Move.
- To see how automated strategies are positioning across this sector, explore Trending AI Robots.
Introduction
Guardant Health (GH) and Natera (NTRA) are two of the most closely watched names in precision diagnostics, a segment of healthcare that uses blood-based (liquid biopsy) testing to detect and monitor cancer and other conditions. Both have been standout performers, making this stock comparison especially relevant for growth-oriented investors and traders weighing momentum against valuation. Because the two companies compete in adjacent markets, understanding their relative performance and market positioning helps clarify where each may hold an edge. This analysis reviews recent business developments, price behavior, and risk profiles to assess which stock the market—and a rules-based AI framework—might currently favor.
GH Overview and Recent Performance
Guardant Health is a precision oncology company focused on blood tests that guide cancer treatment and early detection. Its core franchises include Guardant360 (therapy selection), Reveal (molecular residual disease, or MRD, testing), and Shield, a blood test for colorectal cancer screening. In recent weeks, sentiment has been supported by expanding reimbursement and access for Shield, including coverage from a major national insurer and new state-level legislation removing cost-sharing barriers. The company also highlighted a broad liquid biopsy research portfolio at a recent oncology congress.
On a relative performance basis, GH has been among the stronger momentum names in the group, with revenue accelerating and screening volumes growing rapidly. Still, the company remains unprofitable at the operating level as it invests in commercial infrastructure, and free cash flow is negative. Wall Street sentiment remains constructive, with a consensus "Strong Buy" rating and an average price target above the recent trading range, implying meaningful upside relative to peers.
NTRA Overview and Recent Performance
Natera is a global diagnostics company spanning women's health, oncology, and organ health. Its best-known products include Signatera, a personalized test used to detect MRD and monitor cancer recurrence, and Panorama, a non-invasive prenatal test (NIPT). In recent weeks, Natera presented multiple datasets at a major oncology meeting and reported positive developments across its pipeline, including regulatory milestones for a multi-cancer early detection assay.
Relative to GH, NTRA offers a larger and more diversified revenue base, with strong year-over-year growth and a market capitalization of roughly $60 billion. The stock has traded near its 52-week high following a sustained rally, though it pulled back modestly into a recent earnings date. Analyst consensus is also "Strong Buy," but the average price target sits very close to the current price, suggesting the market has already priced in much of the near-term optimism.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that monitor and trade thousands of tickers across equities, ETFs, forex, and other markets. Because not every bot suits every market regime, Tickeron curates a focused "Trending AI Robots" section that surfaces only the strategies currently performing best under live market conditions. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they cover, so investors can review the section to find approaches aligned with their own objectives and risk tolerance. The curated list is designed to help traders identify momentum-driven opportunities across names like GH and NTRA using quantitative, rules-based signals rather than intuition. Explore the Trending AI Robots page to see which strategies are currently leading.
Head-to-Head Comparison
The clearest contrast between the two companies is focus versus diversification. Guardant Health is concentrated in oncology, with a large part of its growth narrative tied to the early adoption of its Shield screening test. Natera operates a broader portfolio that spans prenatal testing, transplant monitoring, and a market-leading MRD franchise in Signatera, which gives it more revenue streams but also more moving parts.
Growth drivers also differ. GH is leveraging a reimbursement expansion catalyst in screening that is still in relatively early innings, whereas NTRA is monetizing an already-scaled MRD and women's health business. On risk, both remain unprofitable and carry elevated valuations, but NTRA trades with far less cushion to its consensus price target and a higher beta, making it more sensitive to a sentiment shift. Sector exposure is similar—both sit in high-growth diagnostics—but their momentum profiles diverge, with GH showing stronger trailing relative performance.
Tickeron AI Verdict
Weighing trend consistency, catalyst visibility, and relative positioning, Tickeron's AI framework would currently lean toward GH (Guardant Health) in this comparison. The stock's stronger recent momentum, a distinct screening catalyst that is still scaling, and materially greater implied upside to its average analyst target give it a more favorable risk-reward profile under current conditions. NTRA remains a high-quality franchise with superior scale and diversification, but its extended valuation and proximity to consensus targets reduce the near-term margin for error. This assessment is probabilistic rather than definitive and reflects observable market data rather than a forecast of guaranteed returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GH is a StrongBuy and NTRA is a StrongBuy.
Aroon Indicator for GH shows an upward move is likely
GH's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator showed a similar pattern. In 183 of the 210 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on GH as a result. In 69 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for GH just turned positive on October 26, 2026. Looking at past instances where GH's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
GH moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GH crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +4.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in 244 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for GH moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
GH broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-102.803) is normal, around the industry mean (65.876). P/E Ratio (-48.641) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Aroon Indicator for NTRA shows an upward move is likely
NTRA's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 286 similar instances where the Aroon Indicator showed a similar pattern. In 244 of the 286 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +6.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 22 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 65 cases where NTRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 73 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 36 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (29.986) is normal, around the industry mean (65.876). NTRA's P/E Ratio (-280.681) is considerably lower than the industry average of (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
GH | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 61 | 8 | |
SMR RATING 1..100 | 100 | 94 | |
PRICE GROWTH RATING 1..100 | 36 | 35 | |
P/E GROWTH RATING 1..100 | 66 | 86 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (6) in the Biotechnology industry is in the same range as GH (15) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew similarly to GH’s over the last 12 months.
NTRA's Profit vs Risk Rating (8) in the Biotechnology industry is somewhat better than the same rating for GH (61) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew somewhat faster than GH’s over the last 12 months.
NTRA's SMR Rating (94) in the Biotechnology industry is in the same range as GH (100) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew similarly to GH’s over the last 12 months.
NTRA's Price Growth Rating (35) in the Biotechnology industry is in the same range as GH (36) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew similarly to GH’s over the last 12 months.
GH's P/E Growth Rating (66) in the Medical Or Nursing Services industry is in the same range as NTRA (86) in the Biotechnology industry. This means that GH’s stock grew similarly to NTRA’s over the last 12 months.
| GH | NTRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 56% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 79% |
| Advances ODDS (%) | 6 days ago 83% | 6 days ago 80% |
| Declines ODDS (%) | 2 days ago 84% | 2 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GH’s FA Score shows that 1 FA rating(s) are green while NTRA’s FA Score has 2 green FA rating(s).
- GH’s FA Score: 1 green, 4 red.
- NTRA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GH’s TA Score shows that 6 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
- GH’s TA Score: 6 bullish, 4 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
GH (@Medical Specialties) experienced а -1.45% price change this week, while NTRA (@Medical Specialties) price change was -6.42% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.47%. For the same industry, the average monthly price growth was -4.50%, and the average quarterly price growth was +42.79%.
Reported Earning Dates
GH is expected to report earnings on Nov 05, 2026.
NTRA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical Specialties (-1.47% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
GH and
Correlation & Price change
A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ADPT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | -8.54% | ||
| ADPT - NTRA | 55% Loosely correlated | -5.93% | ||
| NEO - NTRA | 55% Loosely correlated | -5.12% | ||
| GH - NTRA | 54% Loosely correlated | -4.51% | ||
| ISRG - NTRA | 53% Loosely correlated | +1.12% | ||
| TMO - NTRA | 48% Loosely correlated | -2.06% | ||
More | ||||